BioClinica, Inc., a global provider of clinical trial management services, announced a strategic partnership with Kaizen Clinical Services, Inc., an oncology-focused contract research organization (CRO).
“Our partnership will enable customers to benefit from Kaizen’s expertise in worldwide oncology trials and BioClinica’s best-in-class product suite offering,” said Peter Benton, President of the eClinical Division of BioClinica. “Kaizen’s oncology focus makes it a strong addition to the BioClinica Certified Partner Program, supporting customers in the complex therapeutic areas of study monitoring and management.”
The BioClinica Certified Partner (“BCP”) Program helps CROs address many of the complexities associated with clinical trials by leveraging the focus and the power of BioClinica software and services. BioClinica solutions enable CROs to start clinical studies more efficiently, optimize data collection, to ensure timely grants payments and track performance. BioClinica solutions provide CROs with the optimal means to more efficiently manage multiple studies with multiple sponsors and to supplement their therapeutic and clinical expertise with BioClinica’s global clinical technology support.
Kaizen Clinical Services, based in Jackson, New Jersey, is a woman-owned contract research organization that focuses on oncology trials. Founded in 2007, Kaizen offers project management, clinical monitoring, consulting and training services. The firm has managed and/or monitored Phase I through Phase IV trials that have enrolled between 35 and 2,500 patients. “We are pleased to join BioClinica in this partnership. Kaizen’s philosophy is to continually improve our services and performance. This relationship with BioClinica and our access to their extensive suite of services will allow us to maintain our philosophy by enabling us to better serve our clients as well as the oncology investigative community as a whole,” said Ernie Stefanelli, President and co-founder of Kaizen Clinical Services, Inc.
Date: December, 2010
Source: BioClinica, Inc.
